FDA Greenlights First Injectable HIV Prevention

Yesterday the FDA approved the first injectable medication for HIV pre-exposure prevention, called Apretude.

Why it matters: Apretude, which can be given every 2 months, is the first HIV prophylactic that does not involve taking a daily pill—a game changer for “certain groups where adherence to daily medication has been a major challenge or not a realistic option,” said one of FDA official.

The numbers: The FDA found the drug reduced the risk of HIV infection by 69% for cisgender men and transgender women who have sex with men, compared to daily oral medications. That number increased to 90% for cisgender women in the second trial.


Related: Headlines linking people with HIV to COVID variants are at best incomplete, at worst stigmatising ​​– aidsmap

Secondary Topic
Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top